Targeting inflammation in chronic thromboembolic pulmonary hypertension
Official title: Targeting Interleukin-17 inflammatory Axis in CTEPH
Funded at University of Colorado Denver · NIH-11131962 · Data updated 2026-11-12
This study is looking at how certain inflammation processes, especially involving a substance called interleukin-17, affect the worsening of chronic thromboembolic pulmonary hypertension (CTEPH) after a blood clot in the lungs, with the hope of finding new treatments for patients who can’t have surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | May 1, 2025 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $723,084 |
| NIH project number | 1R01HL174909-01A1 |
| Project ID | NIH-11131962 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with chronic thromboembolic pulmonary hypertension who are not eligible for surgical intervention.
✕Less likely to help
Patients with acute pulmonary embolism who have not developed chronic thromboembolic pulmonary hypertension may not benefit from this research.
What this research studies
This research investigates chronic thromboembolic pulmonary hypertension (CTEPH), a serious condition that can develop after an acute pulmonary embolism. The study aims to understand how specific inflammatory pathways, particularly those involving interleukin-17, contribute to the progression of CTEPH. By using advanced techniques like single-cell RNA sequencing, researchers will analyze cells from patient thrombi to identify potential new treatments for patients who are not candidates for surgery. The goal is to develop novel medical therapies that can improve patient outcomes and address the significant unmet needs in CTEPH management.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with CTEPH, improving their quality of life and potentially extending survival.
How similar studies have gone: Other research has shown promise in targeting inflammatory pathways in similar conditions, suggesting that this approach could be effective in CTEPH as well.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Yu, Yen-Rei Andrea — University of Colorado Denver
- Study coordinator: Yu, Yen-Rei Andrea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.